Protection of bone in premenopausal women with breast cancer: focus on zoledronic acid

References

• JemalASiegelRXuJWardECancer statistics, 2010CA Cancer J Clin201060527730020610543
   PubMed Web of Science ®Google Scholar
• ColemanRESkeletal complications of malignancyCancer1997808 Suppl158815949362426
   PubMed Web of Science ®Google Scholar
• MundyGRMetastasis to bone: causes, consequences and therapeutic opportunitiesNat Rev Cancer20022858459312154351
   PubMed Web of Science ®Google Scholar
• SaadFNew research findings on zoledronic acid: survival, pain, and anti-tumour effectsCancer Treat Rev200834218319218061356
   PubMed Web of Science ®Google Scholar
• WeinfurtKPLiYCastelLDThe significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancerAnn Oncol200516457958415734776
   PubMed Web of Science ®Google Scholar
• National Osteoporosis FoundationClinician’s Guide to Prevention and Treatment of OsteoporosisWashington, DCNational Osteoporosis Foundation2010 Available from: http://www.nof.orgAccessed 4 April 2012
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet200536594721687171715894097
   PubMed Web of Science ®Google Scholar
• EastellRAdamsJEColemanREEffect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230J Clin Oncol20082671051105718309940
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGfor Austrian Breast and Colorectal Cancer Study Group (ABSCG)Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudyLancet Oncol20089984084918718815
   PubMed Web of Science ®Google Scholar
• ShapiroCLHalabiSHarsVZoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809Eur J Cancer201147568368921324674
   PubMed Web of Science ®Google Scholar
• VehmanenLElomaaIBlomqvistCSaartoTTamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual statusJ Clin Oncol200624467568016446340
   PubMed Web of Science ®Google Scholar
• HadjiPAromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosisCrit Rev Oncol Hematol2009691738218757208
   PubMed Web of Science ®Google Scholar
• Zometa^® (zoledronic acid) [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2011
   Google Scholar
• Aredia^® (pamidronate) injection [package insert]East Hanover, NJNovartis Pharmaceuticals Corporation2008
   Google Scholar
• DelmasPDBalenaRConfravreuxEHardouinCHardyPBremondABisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled studyJ Clin Oncol19971539559629060533
   PubMed Web of Science ®Google Scholar
• FuleihanGESalamounMMouradYAPamidronate in the prevention of chemotherapy-induced bone loss in premenopausal women with breast cancer: a randomized controlled trialJ Clin Endocrinol Metab20059063209321415769994
   PubMed Web of Science ®Google Scholar
• HershmanDLMcMahonDJCrewKDZoledronic acid prevents bone loss in premenopausal women undergoing adjuvant chemotherapy for early-stage breast cancerJ Clin Oncol200826294739474518711172
   PubMed Web of Science ®Google Scholar
• HershmanDLMcMahonDJCrewKDPrevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatmentJ Clin Endocrinol Metab201095255956620022990
   PubMed Web of Science ®Google Scholar
• KimJEAhnJHJungKHZoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01)Breast Cancer Res Treat201112519910620922564
   PubMed Web of Science ®Google Scholar
• PowlesTJMcCloskeyEPatersonAHOral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancerJ Natl Cancer Inst19989097047089586668
   PubMed Web of Science ®Google Scholar
• FrithJCMonkkonenJBlackburnGMRussellRGRogersMJClodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitroJ Bone Miner Res1997129135813679286751
   PubMed Web of Science ®Google Scholar
• FritzGTargeting the mevalonate pathway for improved anticancer therapyCurr Cancer Drug Targets20099562663819508172
   PubMed Web of Science ®Google Scholar
• KavanaghKLGuoKDunfordJEThe molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugsProc Natl Acad Sci U S A2006103207829783416684881
   PubMed Web of Science ®Google Scholar
• RussellRGBisphosphonates: mode of action and pharmacologyPediatrics2007119Suppl 2S150S16217332236
   PubMed Web of Science ®Google Scholar
• LuckmanSPHughesDECoxonFPGrahamRRussellGRogersMJNitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including RasJ Bone Miner Res19981345815899556058
   PubMed Web of Science ®Google Scholar
• MonkkonenHAuriolaSLehenkariPA new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonatesBr J Pharmacol2006147443744516402039
   PubMed Web of Science ®Google Scholar
• Xgeva^® (denosumab) [package insert]Thousand Oaks, CAAmgen Inc2010
   Google Scholar
• PavlakisNSchmidtRStocklerMBisphosphonates for breast cancerCochrane Database Syst Rev20053CD00347416034900
   PubMedGoogle Scholar
• Food and Drug Administration Center for Drug Evaluation and ResearchOncologic Drugs Advisory Committee MeetingMarch 4, 2005Aredia/Zometa Available from: www.fda.govAccessed 4 April 2012
   Google Scholar
• RosenLSGordonDKaminskiMLong-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trialCancer20039881735174414534891
   PubMed Web of Science ®Google Scholar
• StopeckATLiptonABodyJJDenosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind studyJ Clin Oncol201028355132513921060033
   PubMed Web of Science ®Google Scholar
• Van PoznakCHTeminSYeeGCAmerican Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancerJ Clin Oncol20112991221122721343561
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines)®Breast Cancer Version 12012
   Google Scholar
• SaartoTBlomqvistCValimakiMMakelaPSarnaSElomaaIChemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patientsJ Clin Oncol1997154134113479193325
   PubMed Web of Science ®Google Scholar
• CummingsSRSan MartinJMcClungMRDenosumab for prevention of fractures in postmenopausal women with osteoporosisN Engl J Med2009361875676519671655
   PubMed Web of Science ®Google Scholar
• EllisGKBoneHGChlebowskiRRandomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancerJ Clin Oncol200826304875488218725648
   PubMed Web of Science ®Google Scholar
• BlackDMDelmasPDEastellRfor HORIZON Pivotal Fracture TrialOnce-yearly zoledronic acid for treatment of postmenopausal osteoporosisN Engl J Med2007356181809182217476007
   PubMed Web of Science ®Google Scholar
• BrufskyAMHarkerWGBeckJTFinal 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozoleCancer201211851192120121987386
   PubMed Web of Science ®Google Scholar
• EidtmannHde BoerRBundredNEfficacy of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: 36-month results of the ZO-FAST StudyAnn Oncol201021112188219420444845
   PubMed Web of Science ®Google Scholar
• LlombartAFrassoldatiAPaijaOImmediate administration of zoledronic acid reduces aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer: 12-month analysis of the E-ZO-FAST trialClin Breast Cancer2012121404822014381
   PubMed Web of Science ®Google Scholar
• HinesSLMinceyBASloanJAPhase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancerJ Clin Oncol20092771047105319075260
   PubMed Web of Science ®Google Scholar
• GnantMZoledronic acid in the treatment of early-stage breast cancer: is there a final verdict?Curr Oncol Rep2012141354322113793
   PubMed Web of Science ®Google Scholar
• GnantMFKauraSSofryginODeleaTECost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer (BC) enrolled in the ABCSG-12 study [poster]Presented at: IMPAKT-Breast Cancer ConferenceMay 7–9, 2009Brussels, BelgiumAbstract 73P
   Google Scholar
• HamiltonEClayTMBlackwellKLNew perspectives on zoledronic acid in breast cancer: potential augmentation of anticancer immune responseCancer Invest201129853354121843051
   PubMed Web of Science ®Google Scholar
• ThurstonSJZeltSCBottemanMCost-effectiveness of zoledronic acid (ZOL) for the treatment of bone loss in postmenopausal women with early-stage breast cancer receiving aromatase inhibitors in the United States (US)J Clin Oncol201028SupplAbstract e11007
   Web of Science ®Google Scholar
• WinterMCHolenIColemanREExploring the anti-tumour activity of bisphosphonates in early breast cancerCancer Treat Rev200834545347518423992
   PubMed Web of Science ®Google Scholar
• WuEQXieJSignorovitchJDienerMSorgRNamjoshiMNumber needed to treat and treatment cost per fracture avoided with denosumab compared with zoledronic acid in patients with breast cancer with bone metastases [poster]Presented at: 2011 ASCO Breast Cancer SymposiumSeptember 8–10, 2011San Francisco, CAAbstract 151
   Google Scholar
• Candelaria-QuintanaDDayaoZRRoyceMEThe role of antiresorptive therapies in improving patient care in early and metastatic breast cancerBreast Cancer Res Treat2012132235536321987034
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBSchippingerWfor ABSCG-12 Trial InvestigatorsEndocrine therapy plus zoledronic acid in premenopausal breast cancerN Engl J Med2009360767969119213681
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBLuschin-EbengreuthGLong-term follow-up in ABCSG-12: significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with hormone-receptor- positive early breast cancer [oral]Presented at: 2011 CTRC-AACR San Antonio Breast Cancer SymposiumDecember 6–10, 2011San Antonio, TXAbstract S1S2
   Google Scholar
• MeadsMBHazlehurstLADaltonWSThe bone marrow microenvironment as a tumor sanctuary and contributor to drug resistanceClin Cancer Res20081492519252618451212
   PubMed Web of Science ®Google Scholar
• ShiozawaYHavensAMPientaKJTaichmanRSThe bone marrow niche: habitat to hematopoietic and mesenchymal stem cells, and unwitting host to molecular parasitesLeukemia200822594195018305549
   PubMed Web of Science ®Google Scholar
• CoghlinCMurrayGICurrent and emerging concepts in tumour metastasisJ Pathol2010222111520681009
   PubMed Web of Science ®Google Scholar
• AftRNaughtonMTrinkausKEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trialLancet Oncol201011542142820362507
   PubMed Web of Science ®Google Scholar
• LinAYParkJWScottJZoledronic acid as adjuvant therapy for women with early stage breast cancer and disseminated tumor cells in bone marrow [abstract]J Clin Oncol200826Suppl20sAbstract 559
   PubMed Web of Science ®Google Scholar
• RackBJuckstockJGenssEMEffect of zoledronate on persisting isolated tumour cells in patients with early breast cancerAnticancer Res20103051807181320592383
   PubMed Web of Science ®Google Scholar
• SolomayerEFGebauerGHirnlePInfluence of zoledronic acid on disseminated tumor cells (DTC) in primary breast cancer patients [poster]Presented at: 31st Annual San Antonio Breast Cancer SymposiumDecember 10–14, 2008San Antonio, TXAbstract 2048
   Google Scholar
• KimMYOskarssonTAcharyyaSTumor self-seeding by circulating cancer cellsCell200913971315132620064377
   PubMed Web of Science ®Google Scholar
• ColemanREMarshallHCameronDfor AZURE InvestigatorsBreast-cancer adjuvant therapy with zoledronic acidN Engl J Med2011365151396140521995387
   PubMed Web of Science ®Google Scholar
• GnantMMlineritschBStoegerHfor Austrian Breast and Colorectal Cancer Study Group, Vienna, AustriaAdjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trialLancet Oncol201112763164121641868
   PubMed Web of Science ®Google Scholar
• HoffAOTothBBAltundagKFrequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonatesJ Bone Miner Res200823682683618558816
   PubMed Web of Science ®Google Scholar
• RipamontiCIManiezzoMCampaTDecreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of MilanAnn Oncol200920113714518647964
   PubMed Web of Science ®Google Scholar
• BadrosATerposEKatodritouENatural history of osteonecrosis of the jaw in patients with multiple myelomaJ Clin Oncol200826365904590919018084
   PubMed Web of Science ®Google Scholar
• ColemanRBundredNde BoerRImpact of zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST, ZO-FAST, and E-ZO-FAST [poster]Presented at: 32nd Annual San Antonio Breast Cancer SymposiumDecember 9–13, 2009San Antonio, TXAbstract 4082
   Google Scholar
• BarlevASongXIvanovBSettyVChungKPayer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancerJ Manag Care Pharm201016969370221067255
   PubMed Web of Science ®Google Scholar
• ZhouZRedaelliAJohnellOWillkeRJMassiminiGA retrospective analysis of health care costs for bone fractures in women with early-stage breast carcinomaCancer2004100350751714745866
   PubMed Web of Science ®Google Scholar